Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
ConditionPancreatic Adenocarcinoma Metastatic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Paoli-Calmettes
About this trial
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.
Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Eligibility criteria
Qualifiers
Age > 18 years
Signed written informed consent specific to the PROMETAP study
Affiliation with a social security system
Treatment and follow-up performed at the Institut Paoli-Calmettes
Disqualifiers
None
Trial design
Treatments tested in this trial
- Biopsy collection
- Blood collection
Treatment groups
64 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov